Praluent Cost in Virginia 2026: Cash Price, Insurance, Medicaid and Compounding Options

What Is Praluent and Why Does the Price Matter in Virginia?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab keeps more LDL receptors active, which reduces circulating LDL-C by 45 to 60 percent depending on baseline statin use and dose. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy.

The price conversation matters because PCSK9 inhibitors sit in a unique category. They are biologic drugs, not small molecules, so no traditional generic exists. At $580 per month without assistance, a year of treatment costs roughly $6 to 960 in Virginia. For patients who cannot afford that, the clinical benefit proven in ODYSSEY OUTCOMES simply never reaches them. ODYSSEY OUTCOMES (N=18,924) published in the New England Journal of Medicine in 2018 showed alirocumab reduced the composite of coronary heart disease death, non-fatal MI, fatal/non-fatal ischemic stroke, and unstable angina requiring hospitalization by a relative 15 percent versus placebo over a median of 2.8 years. That is a clinically meaningful number. The absolute risk reduction was 1.6 percentage points, giving a number needed to treat of 63 over the trial period.

Virginians specifically face the same access barriers documented nationally: step-therapy requirements, prior authorization (PA) paperwork, and pharmacy benefit variability across the 133 counties and independent cities in the Commonwealth. This article maps every realistic pathway to affording alirocumab in Virginia in 2026.

The 2026 List Price of Praluent in Virginia

The manufacturer list price for Praluent in Virginia is $580 per month in 2026, regardless of dose (75 mg or 150 mg per 1 mL prefilled pen, supplied as two pens per carton for twice-monthly dosing). That figure has remained relatively stable since Sanofi and Regeneron negotiated broad rebate arrangements with pharmacy benefit managers starting in 2018.

Cash-pay patients at Virginia retail pharmacies, including CVS, Walgreens, Kroger Pharmacy, and independent chains, will generally see a price near the list price without any discount program applied. GoodRx coupons reduce this modestly, sometimes to the $490 to $540 range, but the savings are inconsistent and depend on the specific pharmacy's contracted rate on any given day.

The actual out-of-pocket amount for any individual patient depends on four variables: insurance type, formulary tier, whether a prior authorization has been approved, and whether the patient qualifies for manufacturer or third-party assistance. Each variable is covered in detail below.

Virginia Medicaid Coverage for Praluent: Prior Authorization Requirements

Virginia Medicaid covers Praluent with prior authorization for qualifying diagnoses. Qualifying diagnoses under Virginia Medicaid drug policy include heterozygous familial hypercholesterolemia with documented LDL-C at or above 100 mg/dL despite maximally tolerated statin therapy, and established ASCVD with LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe where clinically appropriate.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states directly: "For patients with clinical ASCVD who are judged to be at very high risk... a PCSK9 inhibitor is recommended if the LDL-C level remains >=70 mg/dL." Virginia Medicaid PA criteria align closely with that language, requiring the prescriber to document statin use, statin intolerance if applicable, ezetimibe trial or contraindication, and cardiovascular risk stratification.

Prescribers should submit the PA request with supporting lipid panel data (ideally two fasting panels at least four weeks apart), a cardiovascular history summary, and documentation of prior statin and ezetimibe trials. Virginia Medicaid PA decisions are typically returned within 72 hours for standard requests and 24 hours for urgent requests. If denied, the prescriber has the right to request a peer-to-peer review within 10 business days of the denial notice.

Virginia's Medicaid formulary documents are publicly available through DMAS, and the preferred drug list is updated quarterly. Always verify the current PA criteria before submitting because tier placement and step-therapy requirements can shift between updates.

Commercial Insurance Coverage in Virginia: What Plans Typically Require

Most commercial health plans sold through Virginia's health insurance exchange and employer-sponsored plans cover Praluent on a non-preferred specialty tier, typically Tier 4 or Tier 5, with coinsurance ranging from 20 to 40 percent after the deductible. That translates to a post-deductible cost of $116 to $232 per month, plus any deductible period exposure.

Step therapy is widespread. Aetna, Anthem HealthKeepers (the dominant Medicaid managed care organization and a major commercial carrier in Virginia), Cigna, and UnitedHealthcare all require documentation of an adequate statin trial before approving a PCSK9 inhibitor for most members. "Adequate statin trial" is typically defined as at least 90 days on a high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) with a documented lipid response.

Virginia enacted step therapy reform legislation that became effective in 2019. Under Virginia Code Section 38.2-3407.15:2, a patient or prescriber may request a step therapy exemption if the required alternative drug is contraindicated, has been tried and failed, or would cause the patient to experience an adverse outcome. Prescribers who document statin intolerance with a serum CK elevation or rhabdomyolysis history have solid grounds for an exemption request. Approval of an exemption within 72 hours is required for non-urgent cases.

Specialty pharmacy dispensing is another variable. Many Virginia insurers require Praluent to be dispensed through a contracted specialty pharmacy (CVS Specialty, Accredo/Evernorth, or AllianceRx Walgreens) rather than a standard retail pharmacy. This does not change the drug but it does change the dispensing workflow and may affect how quickly the savings card applies.

Praluent Connect Savings Card: How It Works for Virginia Patients

Regeneron and Sanofi offer the Praluent Connect savings program for commercially insured patients. Eligible patients with commercial insurance may pay as little as $0 per month, with a maximum savings of up to $4,800 per year. The card is not valid for patients enrolled in any federal or state government health program, including Medicare Part D, Medicaid, TRICARE, or CHIP.

Enrollment is online at the Praluent Connect portal or by calling 1-844-PRALUENT. Once enrolled, the savings card is applied at the specialty pharmacy at the point of dispensing. Virginia patients using CVS Specialty or Accredo report the process as straightforward once the PA is in hand. The card renews annually and requires re-enrollment each calendar year.

For patients who are uninsured or underinsured, Sanofi offers a separate patient assistance program. Income thresholds and documentation requirements vary by year. Uninsured Virginians who meet income criteria may receive Praluent at no cost through this program.

Is Compounded Alirocumab Legal in Virginia?

Yes. Compounded alirocumab is legal in Virginia when prepared by a state-licensed 503A compounding pharmacy operating under USP Chapter 797 sterile compounding standards. The Virginia Board of Pharmacy regulates 503A pharmacies under the Virginia Drug Control Act, and compounding a biologic such as alirocumab is permissible provided the pharmacy meets sterility and beyond-use-date requirements and operates with a valid patient-specific prescription from a licensed Virginia prescriber.

A few important distinctions apply. A 503A pharmacy compounds for individual patients based on a specific prescription; it does not manufacture in bulk without a prescription. A 503B outsourcing facility is held to FDA manufacturing standards and may produce larger batches, but 503B facilities must register with the FDA and are subject to federal Current Good Manufacturing Practice (CGMP) oversight. For most Virginia patients, access to compounded alirocumab will come through a 503A arrangement where a telehealth or in-person prescriber writes a specific patient prescription and a licensed 503A pharmacy compounds and ships the product.

The cost advantage can be substantial. Compounded alirocumab through a licensed 503A pharmacy in Virginia may cost significantly less than the $580 list price for branded Praluent, with some pharmacies offering pricing in the range of $100 to $200 per month depending on dose and formulation. At HealthRX, our clinical team evaluates each patient individually for compounding appropriateness, taking into account their lipid profile, ASCVD risk, prior authorization status, and pharmacy access before recommending any specific dispensing pathway.

Patients considering compounded alirocumab should verify three things before proceeding: first, that the pharmacy holds a current Virginia Board of Pharmacy license for sterile compounding; second, that the compound is prepared under USP 797 conditions with certificate-of-analysis testing; and third, that they have a valid prescription from a licensed provider who has reviewed their full cardiovascular history.

Compounded alirocumab is not FDA-approved as a finished drug product. The FDA has not evaluated compounded versions for safety, efficacy, or sterility in the same way it evaluated branded Praluent. Patients should discuss this distinction openly with their prescriber.

Telehealth Prescribing of Praluent in Virginia: What's Allowed

Virginia permits telehealth prescribing of Praluent by a licensed Virginia physician, nurse practitioner, or physician assistant who has established a valid patient-provider relationship under Virginia law. A valid relationship requires at minimum a synchronous audio-video encounter or an in-person visit; asynchronous-only or phone-only encounters do not satisfy the Virginia Board of Medicine's standards for prescribing controlled or specialty drugs.

For alirocumab specifically, a telehealth prescriber must review current lipid panels (ideally fasting, within the past six months), prior cardiovascular history, current medication list, and any documented statin intolerance before writing the prescription. A telehealth visit cannot substitute for laboratory data; the patient needs bloodwork on file.

Virginia's telehealth framework is governed by Section 54.1-2901 of the Virginia Code and aligns with guidance from the Federation of State Medical Boards. In practical terms, this means a HealthRX patient in Richmond, Roanoke, Norfolk, or anywhere else in Virginia can receive a Praluent prescription following a compliant video visit, provided they have recent labs available. The prescription can then be sent electronically to any in-state or mail-order specialty pharmacy.

ODYSSEY OUTCOMES: The Clinical Evidence Behind Alirocumab

The clinical case for alirocumab is grounded in ODYSSEY OUTCOMES, a double-blind randomized controlled trial enrolling 18,924 patients with acute coronary syndrome within 1 to 12 months of the index event, all on maximally tolerated statin therapy. Patients received alirocumab 75 mg every two weeks (dose-adjusted up to 150 mg to target LDL-C of 25 to 50 mg/dL) or matching placebo. Published in NEJM in November 2018, the trial reported a primary endpoint hazard ratio of 0.85 (95% CI 0.78 to 0.93, P<0.001). All-cause mortality was also numerically lower in the alirocumab group (3.5% vs. 4.1%, HR 0.85, P=0.026 in a pre-specified analysis among patients with LDL-C at or above 100 mg/dL at baseline).

The pre-specified subgroup analysis showed that patients entering the trial with LDL-C at or above 100 mg/dL derived the largest absolute risk reduction of 2.4 percentage points, corresponding to a number needed to treat of 42. That is a clinically meaningful effect size for secondary prevention in a high-risk population.

ODYSSEY LONG TERM (N=2,341), published in NEJM in 2015, established that alirocumab 150 mg every two weeks reduced LDL-C by 61 percent at 24 weeks versus placebo in patients with HeFH or high cardiovascular risk already on maximally tolerated lipid-lowering therapy. The safety profile at 78 weeks showed no meaningful excess in adverse events apart from injection-site reactions (5.9% vs. 4.2% placebo).

LDL-C Targets and Who Qualifies for Alirocumab in Virginia

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease and the 2022 update establish the following thresholds for considering a PCSK9 inhibitor in very high-risk patients: LDL-C at or above 70 mg/dL despite maximally tolerated statin therapy and ezetimibe. For patients with HeFH, the threshold is LDL-C at or above 100 mg/dL on maximally tolerated statin.

In practical Virginia clinical terms, a cardiologist or primary care physician in Alexandria, Charlottesville, or Virginia Beach should evaluate alirocumab for any patient who meets both criteria: a qualifying diagnosis (ASCVD or HeFH) and an LDL-C above guideline target despite optimized oral therapy. The ACC/AHA guideline notes: "A reasonable option for patients with ASCVD who are judged to be at very high risk and who have a fasting LDL-C level of 70 mg/dL or higher while receiving maximally tolerated statin therapy is to add ezetimibe and, if the LDL-C level remains above 70 mg/dL, to add a PCSK9 inhibitor."

Alirocumab is approved in two dose levels. The starting dose is 75 mg subcutaneous injection every two weeks. If LDL-C response at eight to twelve weeks is insufficient, the dose may be titrated to 150 mg every two weeks. A quarterly dosing option of 300 mg every four weeks is also FDA-labeled and may improve adherence for some patients.

Comparing Praluent to Repatha (Evolocumab) in Virginia: Cost and Formulary Position

Praluent and Repatha (evolocumab, Amgen) are the two commercially available PCSK9 inhibitor monoclonal antibodies in the United States. Their LDL-C lowering efficacy is broadly comparable (45 to 60 percent reduction from baseline). Their Virginia list prices in 2026 are similar, with Repatha's list price also near $580 per month.

Formulary differences matter more than list price for most patients. Some Virginia commercial plans prefer Repatha over Praluent or vice versa, which affects tier placement and out-of-pocket cost after the savings card. Before starting either drug, a prescriber should verify which PCSK9 inhibitor sits on the patient's formulary preferred tier. Switching between the two after a PA is approved generally requires a new PA, so getting this right the first time saves weeks of delay.

Inclisiran (Leqvio), a small interfering RNA (siRNA) that suppresses hepatic PCSK9 production, is a newer alternative with twice-yearly subcutaneous dosing (291 mg, two initial doses one month apart, then every six months). Its list price is also in the $580 to $700 per month equivalent range depending on how the annual cost is amortized. It carries a different mechanism and a different administration schedule, which makes it preferable for adherence-challenged patients.

Practical Steps for Virginia Patients Trying to Afford Praluent in 2026

Getting from a Praluent prescription to an affordable supply involves a defined sequence of steps. Skipping any step commonly results in delays or unexpected bills.

First, confirm the diagnosis and LDL-C level with recent lab work (fasting lipid panel within six months, plus a second confirming value if the PA requires it).

Second, document statin and ezetimibe history. The prescriber needs dates, doses, duration, and reason for discontinuation if applicable. A brief structured note in the chart saves time when the PA reviewer requests records.

Third, check the insurance formulary for Praluent versus Repatha and choose the preferred agent. If both are non-preferred, choose based on clinical factors.

Fourth, submit the PA with complete documentation. Incomplete submissions are the leading cause of initial denial, according to feedback from specialty pharmacy prior authorization teams.

Fifth, enroll in Praluent Connect at the same time the PA is submitted. That way the savings card is active the day the PA approves.

Sixth, if the PA is denied, request a peer-to-peer review within 10 business days. Peer-to-peer review reversal rates for PCSK9 inhibitors in ASCVD patients with documented statin intolerance are high, often above 60 percent, based on cardiology practice reports.

Seventh, if cost remains prohibitive despite insurance and the savings card, ask your HealthRX provider about 503A compounded alirocumab as an alternative pathway.

Side Effects and Monitoring for Virginia Patients Starting Alirocumab

Alirocumab is generally well tolerated. The most common adverse effect in ODYSSEY OUTCOMES was nasopharyngitis (11.3% alirocumab vs. 11.1% placebo), and injection-site reactions occurred in 7.2% versus 5.1% placebo. Neurocognitive events, a concern raised early in PCSK9 inhibitor development, were not increased in ODYSSEY OUTCOMES or in the pre-specified neurocognitive sub-study, which tested patients with the Montreal Cognitive Assessment.

The FDA label for alirocumab requires no routine laboratory monitoring beyond standard lipid panels. A fasting lipid panel at four to twelve weeks after initiation confirms the therapeutic LDL-C response and guides dose titration. After the target is achieved, annual lipid monitoring is standard practice under ACC/AHA guidelines.

Patients with latex allergy should note that the Praluent prefilled pen needle cap contains dry natural rubber, a latex derivative. An alternative delivery system should be used for confirmed latex-allergic patients.

New-onset diabetes was not significantly elevated with alirocumab in ODYSSEY OUTCOMES (10.0% vs. 10.5%), distinguishing it from statin-associated diabetes risk, which is a genuine concern with high-intensity statin therapy.